A Randomized, Double-blind, Parallel Group, Multicenter, Stratified Study Evaluating the Efficacy and Safety of Repeat Doses of GSK3772847 Compared With Placebo in Participants With Moderately Severe Asthma
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2018
At a glance
- Drugs GSK-3772847 (Primary) ; Fluticasone propionate; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 19 Dec 2017 Planned End Date changed from 8 Nov 2018 to 9 May 2019.
- 19 Dec 2017 Planned primary completion date changed from 16 Aug 2018 to 14 Feb 2019.